SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in MacroGenics
Beneficial Ownership Report
Investment firm Armistice Capital, LLC and its managing member Steven Boyd have reported a 9.99% beneficial ownership stake in biopharmaceutical company MacroGenics, Inc. as of December 31, 2024.
Summary
- Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in MacroGenics, Inc.
- As of December 31, 2024, the Reporting Persons beneficially own an aggregate of 6,276,000 shares of MacroGenics, Inc. Common Stock.
- This ownership represents 9.99% of the total class of securities outstanding.
- The percentage is calculated based on 62,763,448 shares outstanding as of November 1, 2024, as reported in MacroGenics' Form 10-Q filed on November 5, 2024.
- Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd., exercises shared voting and dispositive power over these securities.
- Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing (Schedule 13G) reporting beneficial ownership. It contains no subjective language, forward-looking statements, or performance data that would indicate a positive or negative sentiment. Therefore, the sentiment is neutral.
Industry Context
This filing is a standard disclosure of a significant ownership stake by an investment firm in a publicly traded biopharmaceutical company. Such filings provide transparency regarding institutional holdings but do not typically include broader industry analysis or strategic commentary.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holding, which can influence market perception and potentially signal investor confidence or interest in the company.
Key Dates
| Date | Description |
|---|---|
| 2024-11-01 | Date as of which 62,763,448 shares of MacroGenics, Inc. Common Stock were reported outstanding in the Issuer's Form 10-Q. |
| 2024-12-31 | Date of event which requires the filing of this statement, reflecting the beneficial ownership position. |
| 2025-02-14 | Date the Schedule 13G Amendment No. 3 was filed with the SEC. |
Keywords
MacroGenics, Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management, Biopharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.